TrialSignal transduction and targeted therapy2022

Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.

Nawal Al Kaabi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.